LaserOptek Co Ltd

LaserOptek has a market price of 4,870 KRW per share and a market capitalization of 72.29 billion KRW, with a price-to-book ratio of 3.26 and a price-to-tangible-book ratio of 3.26. The company's enterprise value to EBITDA is negative at -6.47, and its enterprise value to revenue is 2.99. The company's liquidity position is characterized by a current ratio of 2.31, but it has negative net cash after subtracting total debt. The company's profitability is weak, with a return on equity of -48.44% and a return on assets of -29.39%. These metrics are below the typical performance of the Advanced Medical Equipment & Technology industry, which is expected to maintain higher returns due to the capital-intensive and high-margin nature of medical device manufacturing. LaserOptek's revenue is concentrated in disclosed geographic markets, including Korea, Asia, the Middle East, Europe, and the United States. However, the company does not provide segment-specific revenue breakdowns, making it difficult to assess geographic or product concentration risk. The company's growth trajectory is uncertain, with no outlook data provided for the current or next fiscal year. Historical financials show a revenue of 25.70 billion KRW, but the company reported a net loss of 10.74 billion KRW and an operating loss of 11.87 billion KRW, indicating a challenging operating environment. Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's negative operating and free cash flows suggest potential pressure to raise capital, which could lead to future dilution. Recent events include the latest financial filing, which shows a significant operating and net loss. No recent earnings call transcripts or other material events are disclosed in the provided data.